BBSI vs INSP vs NVCR vs TRI

For growth investors, Inspire Medical Systems, Inc.

(INSP) is the stronger pick with 13. 6% revenue growth year-over-year, versus 4. 8% for Thomson Reuters Corporation (TRI). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 9. 3x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate Barrett Business Services, Inc. (BBSI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 9. 3x versus Thomson Reuters Corporation at 27. 5x. On forward P/E, Barrett Business Services, Inc. is actually cheaper at 17. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Barrett Business Services, Inc. wins at 1. 25x versus Thomson Reuters Corporation's 2. 83x — a reasonable growth-adjusted valuation.

Over the past 5 years, Barrett Business Services, Inc.

(BBSI) delivered a total return of +60. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: BBSI returned +326. 4% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thomson Reuters Corporation (TRI) is the lower-risk stock at 0.

38β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 485% more volatile than TRI relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Inspire Medical Systems, Inc.

(INSP) is pulling ahead at 13. 6% versus 4. 8% for Thomson Reuters Corporation (TRI). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -30. 5% for Thomson Reuters Corporation. Over a 3-year CAGR, INSP leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thomson Reuters Corporation (TRI) is the more profitable company, earning 20.

1% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 20. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRI leads at 26. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Barrett Business Services, Inc. (BBSI) is the more undervalued stock at a PEG of 1. 25x versus Thomson Reuters Corporation's 2. 83x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Barrett Business Services, Inc. (BBSI) trades at 17. 1x forward P/E versus 24. 5x for Inspire Medical Systems, Inc. — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INSP: 100. 4% to $91. 33.

In this comparison, TRI (2.

5% yield), BBSI (1. 1% yield) pay a dividend. INSP, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Thomson Reuters Corporation (TRI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

38), 2. 5% yield, +155. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TRI: +155. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BBSI (Industrials) and INSP (Healthcare) and NVCR (Healthcare) and TRI (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BBSI is a small-cap deep-value stock; INSP is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; TRI is a mid-cap quality compounder stock. BBSI, TRI pay a dividend while INSP, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.